Similar Articles
1331 131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma
1332 Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients
1333 Antiviral drug resistance increases hepatocellular carcinoma: A prospective decompensated cirrhosis cohort study
1334 Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation
1335 Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: Dysregulation and implications for early detection, diagnosis and therapy
1336 “Metroticket” predictor for assessing liver transplantation to treat hepatocellular carcinoma: A single-center analysis in mainland China
1337 Role of innate immunity in the development of hepatocellular carcinoma
1338 Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation
1339 MicroRNA-143 suppresses gastric cancer cell growth and induces apoptosis by targeting COX-2
1340 Multimodal treatment of hepatocellular carcinoma on cirrhosis: An update
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA